TSS
VRDN icon

Two Sigma Securities’s Viridian Therapeutics VRDN Stock Holding History

Two Sigma Securities’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-80
Closed -$17K – 376
2015
Q3 		$17K Buy
+80
New +$28.1K 0.03% 185

Other funds holding VRDN

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return

Two Sigma Securities's VRDN Position: Q4 2015 in Review

Two Sigma Securities sold out of Viridian Therapeutics (VRDN) in Q4 2015, closing a stake of 80 shares — an estimated $17K sold.

Two Sigma Securities first reported a position in VRDN in Q3 2015 and held it in 1 quarter. The position peaked at $17K in Q3 2015. 11 funds tracked by Wall St. Rank hold VRDN as of Q4 2015.

  • Two Sigma Securities reported no remaining Viridian Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Two Sigma Securities sold 80 Viridian Therapeutics shares in Q4 2015, an estimated $17K.
  • Two Sigma Securities first reported a position in Viridian Therapeutics in Q3 2015 and held it in 1 quarter.
  • Two Sigma Securities's Viridian Therapeutics position peaked at $17K in Q3 2015.
  • 11 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2015.

Based on Two Sigma Securities's 13F filing for Q4 2015, filed 16 Feb 2016.